BC008-1A injection for recurrent grade 4 glioma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new injection called BC008-1A for people with a grade 4 glioma (a type of brain cancer) that has come back after standard treatment. The goal is to see if the drug can help control the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a grade 4 glioma (a type of brain tumor) that has come back after standard treatment, and you are not planning surgery.
- You are 18 years or older and your doctor expects you to live at least 12 more weeks.
- You are able to do most daily activities without help (KPS score of 70 or higher).
- You have not been treated with certain immunotherapy drugs (like TIGIT, PD-1, PD-L1, or CTLA-4 inhibitors) before.
- You are not taking high doses of steroids (more than 3 mg of dexamethasone per day) or have not used them in the past month.
- Your tumor is not located in the brainstem, spinal cord, or the covering of the brain (leptomeninges).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
This study tests an experimental drug called NST-628 for people with a type of brain cancer (grade 4 glioma) that has returned or worsened after standard treatment. The drug is given before surgery, and you will have a biopsy or tumor removal to see how the drug works in your tumor.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
This trial tests a new drug, GC001, injected directly into the tumor in people with high-grade gliomas (WHO grade 3 or 4) that have come back or are growing. It may be an option if standard treatments have stopped working.
This trial tests a new drug called BioTTT001 for people whose high-grade brain tumor has come back after standard treatment. The drug is given through a small device placed in the head to deliver it directly to the tumor area.
This trial tests a new cell therapy (P134 cells) for people whose glioblastoma has come back after standard treatments like radiation or chemotherapy. The therapy uses a patient's own immune cells (PBMCs) to target cancer cells that have specific markers (CD44 or CD133). It also requires a small procedure to place a reservoir under the scalp for drug delivery.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.